Published in Proc Natl Acad Sci U S A on March 03, 1998
Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A (2003) 6.46
Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A (2000) 5.65
Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev (2007) 4.91
Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest (2003) 4.79
A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest (2001) 4.35
Liver and adipose expression associated SNPs are enriched for association to type 2 diabetes. PLoS Genet (2010) 3.75
Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab (2012) 3.26
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
Signal transduction of stress via ceramide. Biochem J (1998) 2.86
Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet (2014) 2.38
Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A (1999) 2.33
Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol (1998) 2.28
Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest (2007) 2.23
The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal (2007) 2.16
Small nucleolar RNAs U32a, U33, and U35a are critical mediators of metabolic stress. Cell Metab (2011) 2.16
Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med (2011) 2.14
Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem (2009) 2.13
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A (2000) 2.11
Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins. J Biol Chem (2002) 1.94
The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88
As a matter of fat. Cell Metab (2009) 1.85
Lipotoxicity of the pancreatic beta-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes (2001) 1.70
Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta (2009) 1.69
Palmitate activates autophagy in INS-1E β-cells and in isolated rat and human pancreatic islets. PLoS One (2012) 1.66
Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol (2006) 1.66
Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes (2009) 1.64
Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A (1998) 1.64
Bioinformatic profiling of the transcriptional response of adult rat cardiomyocytes to distinct fatty acids. J Lipid Res (2008) 1.63
Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord (2008) 1.60
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A (1999) 1.58
Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2-diabetes-related peptide. J Am Chem Soc (2008) 1.56
Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. ACS Med Chem Lett (2010) 1.55
Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci U S A (1998) 1.53
Long-chain acyl-CoA synthetases and fatty acid channeling. Future Lipidol (2007) 1.53
The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem (2008) 1.52
Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol (2002) 1.46
Linking endoplasmic reticulum stress to cell death in hepatocytes: roles of C/EBP homologous protein and chemical chaperones in palmitate-mediated cell death. Am J Physiol Endocrinol Metab (2010) 1.44
Carboxypeptidase E mediates palmitate-induced beta-cell ER stress and apoptosis. Proc Natl Acad Sci U S A (2008) 1.39
Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol (2010) 1.35
Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res (2013) 1.31
Triacylglycerol fatty acid composition in diet-induced weight loss in subjects with abnormal glucose metabolism--the GENOBIN study. PLoS One (2008) 1.31
PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation. Diabetes (2008) 1.31
Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis. Environ Health Perspect (2001) 1.31
Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochim Biophys Acta (2009) 1.28
Oxidative stress and beta-cell dysfunction. Pflugers Arch (2010) 1.22
The tumor suppressor cybL, a component of the respiratory chain, mediates apoptosis induction. Mol Biol Cell (2003) 1.22
Nutrigenetics and metabolic disease: current status and implications for personalised nutrition. Nutrients (2013) 1.20
Ceramide dissociates 3'-phosphoinositide production from pleckstrin homology domain translocation. Biochem J (2001) 1.16
Increasing dietary palmitic acid decreases fat oxidation and daily energy expenditure. Am J Clin Nutr (2005) 1.16
Sterol and diacylglycerol acyltransferase deficiency triggers fatty acid-mediated cell death. J Biol Chem (2009) 1.16
Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated beta-cell death. Diabetes (2009) 1.14
Concentration-dependent transitions govern the subcellular localization of islet amyloid polypeptide. FASEB J (2011) 1.14
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol (2014) 1.14
The non-coding RNA gadd7 is a regulator of lipid-induced oxidative and endoplasmic reticulum stress. J Biol Chem (2009) 1.13
De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J (2002) 1.13
Examination of 'lipotoxicity' in skeletal muscle of high-fat fed and ob/ob mice. J Physiol (2009) 1.13
Lipid metabolism, apoptosis and cancer therapy. Int J Mol Sci (2015) 1.11
Potential role for peripheral circadian clock dyssynchrony in the pathogenesis of cardiovascular dysfunction. Sleep Med (2007) 1.10
Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev (2013) 1.10
Cardiac remodeling in a rat model of diet-induced obesity. Can J Cardiol (2010) 1.07
The malonyl-CoA-long-chain acyl-CoA axis in the maintenance of mammalian cell function. Biochem J (1999) 1.07
Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids. Am J Physiol Renal Physiol (2010) 1.07
Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne) (2013) 1.07
Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol (2010) 1.07
Type 2 diabetes: etiology and reversibility. Diabetes Care (2013) 1.06
Application of metabolic flux analysis to identify the mechanisms of free fatty acid toxicity to human hepatoma cell line. Biotechnol Bioeng (2008) 1.03
Increased mitochondrial fatty acid oxidation is sufficient to protect skeletal muscle cells from palmitate-induced apoptosis. J Biol Chem (2010) 1.03
A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PLoS One (2010) 1.02
Roles of ceramide and sphingolipids in pancreatic β-cell function and dysfunction. Islets (2012) 1.02
Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients. Obesity (Silver Spring) (2011) 1.02
Mechanisms involved in the cytotoxic and cytoprotective actions of saturated versus monounsaturated long-chain fatty acids in pancreatic beta-cells. J Endocrinol (2007) 1.01
Gene-nutrient interactions with dietary fat modulate the association between genetic variation of the ACSL1 gene and metabolic syndrome. J Lipid Res (2010) 0.99
A role for aberrant protein palmitoylation in FFA-induced ER stress and β-cell death. Am J Physiol Endocrinol Metab (2012) 0.98
Fatty diabetic lung: altered alveolar structure and surfactant protein expression. Am J Physiol Lung Cell Mol Physiol (2010) 0.98
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol (2012) 0.98
Oxidation of HRas cysteine thiols by metabolic stress prevents palmitoylation in vivo and contributes to endothelial cell apoptosis. FASEB J (2011) 0.97
Candidate genes for plasma triglyceride, FFA, and glucose revealed from an intercross between inbred mouse strains NZB/B1NJ and NZW/LacJ. J Lipid Res (2008) 0.97
Pancreatic steatosis and its relationship to β-cell dysfunction in humans: racial and ethnic variations. Diabetes Care (2012) 0.97
Apoptotic sphingolipid ceramide in cancer therapy. J Lipids (2011) 0.97
Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. Curr Opin Lipidol (2010) 0.96
Role of ceramide in diabetes mellitus: evidence and mechanisms. Lipids Health Dis (2013) 0.95
PPARdelta is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction. J Lipid Res (2009) 0.95
Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Am J Physiol Endocrinol Metab (2009) 0.94
Ablation of dihydroceramide desaturase 1, a therapeutic target for the treatment of metabolic diseases, simultaneously stimulates anabolic and catabolic signaling. Mol Cell Biol (2013) 0.93
The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab (2010) 0.93
Variation in characteristics of islets of Langerhans in insulin-resistant, diabetic and non-diabetic-rat strains. Int J Exp Pathol (2010) 0.93
Loss of Ncb5or results in impaired fatty acid desaturation, lipoatrophy, and diabetes. J Biol Chem (2008) 0.92
Haploinsufficiency of RanBP2 is neuroprotective against light-elicited and age-dependent degeneration of photoreceptor neurons. Cell Death Differ (2008) 0.92
Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. J Lipid Res (2011) 0.92
Deletion of PKCepsilon selectively enhances the amplifying pathways of glucose-stimulated insulin secretion via increased lipolysis in mouse beta-cells. Diabetes (2009) 0.92
Expression of apolipoprotein B in the kidney attenuates renal lipid accumulation. J Biol Chem (2010) 0.92
Regulatory role of leptin in glucose and lipid metabolism in skeletal muscle. Indian J Endocrinol Metab (2012) 0.92
Sphingolipids in obesity, type 2 diabetes, and metabolic disease. Handb Exp Pharmacol (2013) 0.91
Characterisation of age-dependent beta cell dynamics in the male db/db mice. PLoS One (2013) 0.91
Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. Brain Res (2010) 0.91
Glycerophospholipid and sphingolipid species and mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. PLoS One (2014) 0.91
Chronic glucolipotoxic conditions in pancreatic islets impair insulin secretion due to dysregulated calcium dynamics, glucose responsiveness and mitochondrial activity. BMC Cell Biol (2013) 0.91
Saturated fatty acid metabolism is key link between cell division, cancer, and senescence in cellular and whole organism aging. Age (Dordr) (2010) 0.90
Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age. Am J Pathol (2000) 0.90
Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function. J Anat (2010) 0.89
A rapid method of total lipid extraction and purification. Can J Biochem Physiol (1959) 173.74
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem (1982) 27.26
Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras- and sis-transformed normal rat kidney cells. J Biol Chem (1986) 5.78
Programmed cell death induced by ceramide. Science (1993) 5.43
Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes (1995) 4.33
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A (1994) 4.01
Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A (1997) 3.79
Cellular composition of the human diabetic pancreas. Diabetologia (1983) 2.71
Sphingolipid metabolism and cell growth regulation. FASEB J (1996) 2.53
Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest (1997) 2.45
Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem (1995) 2.43
An update of the enzymology and regulation of sphingomyelin metabolism. Biochim Biophys Acta (1990) 2.17
Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J Biol Chem (1990) 1.99
Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J Biol Chem (1997) 1.98
Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes (1988) 1.86
Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J Clin Invest (1992) 1.82
Preliminary characterization of calcium binding in islet-cell plasma membranes. Diabetologia (1980) 1.75
Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes (1997) 1.66
Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes. J Biol Chem (1996) 1.53
Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia (1995) 1.52
Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes (1995) 1.51
Engineering of glycerol-stimulated insulin secretion in islet beta cells. Differential metabolic fates of glucose and glycerol provide insight into mechanisms of stimulus-secretion coupling. J Biol Chem (1997) 1.41
Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol (1996) 1.41
Fas-induced apoptosis of T cells occurs independently of ceramide generation. Proc Natl Acad Sci U S A (1997) 1.31
Standardization of insulin secretion from pancreatic islets: validation of a DNA assay. Horm Metab Res (1985) 1.18
Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity. J Clin Invest (1997) 1.15
Selective inhibition of inducible nitric oxide synthase by aminoguanidine. Methods Enzymol (1996) 1.02
Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism (1993) 1.02
Lipid rafts reconstituted in model membranes. Biophys J (2001) 9.19
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost (2001) 6.16
Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A (2000) 5.65
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest (1970) 4.74
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A (1994) 4.01
Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci (1969) 3.42
Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med (1970) 3.27
Partitioning of Thy-1, GM1, and cross-linked phospholipid analogs into lipid rafts reconstituted in supported model membrane monolayers. Proc Natl Acad Sci U S A (2001) 3.12
Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A (1997) 3.07
Functional subdivision of islets of Langerhans and possible role of D cells. Lancet (1975) 2.83
Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. J Clin Invest (1968) 2.60
Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem (1998) 2.59
Glucagon levels and metabolic effects in fasting man. J Clin Invest (1970) 2.58
Two-photon fluorescence microscopy of laurdan generalized polarization domains in model and natural membranes. Biophys J (1997) 2.56
The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet (1975) 2.54
The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. J Clin Invest (1967) 2.53
Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest (1984) 2.52
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet (2000) 2.49
Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia (1985) 2.48
Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose. J Clin Invest (1968) 2.46
Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest (1997) 2.45
Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem (1995) 2.43
Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A (1999) 2.33
[Co-morbidity in acutely hospitalised older patients as a risk factor for death in hospital or within 3 months after discharge]. Ned Tijdschr Geneeskd (2007) 2.17
The effect of experimental insulin deficiency on glucagon secretion. J Clin Invest (1971) 2.15
Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. Proc Natl Acad Sci U S A (1996) 2.15
Systematic review of survival after acute mesenteric ischaemia according to disease aetiology. Br J Surg (2004) 2.14
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A (2000) 2.11
Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost (2004) 2.09
Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. J Thromb Haemost (2015) 2.02
Inhibition of glucose transport into rat islet cells by immunoglobulins from patients with new-onset insulin-dependent diabetes mellitus. N Engl J Med (1990) 2.01
Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes (1982) 1.94
Reversing adipocyte differentiation: implications for treatment of obesity. Proc Natl Acad Sci U S A (1999) 1.92
Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation (2000) 1.91
Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med (1979) 1.88
Effects of starvation on plasma pancreatic glucagon in normal man. Diabetes (1969) 1.86
Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. Diabetes (1971) 1.85
Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes. Science (1990) 1.85
Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes (2001) 1.84
Physiology and pathophysiology of glucagon. Physiol Rev (1976) 1.79
A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med (1966) 1.79
Entero-insular axis. Arch Intern Med (1969) 1.74
The role of aminogenic glucagon secretion in blood glucose homeostasis. J Clin Invest (1969) 1.71
Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. J Clin Invest (1968) 1.71
Large glucagon immunoreactivity in extracts of pancreas. J Biol Chem (1970) 1.70
Control of pancreatic glucagon secretion by glucose. Diabetes (1969) 1.69
Glucagon physiology and pathophysiology in the light of new advances. Diabetologia (1985) 1.69
Novel form of lipolysis induced by leptin. J Biol Chem (1999) 1.67
Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes (1997) 1.66
Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. Am J Med (1973) 1.66
Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med (1981) 1.66
Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem (2000) 1.65
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci U S A (1998) 1.64
Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med (1994) 1.63
Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax (2004) 1.63
Abnormal pancreatic alpha-cell function in bacterial infections. N Engl J Med (1973) 1.62
Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. Proc Natl Acad Sci U S A (1997) 1.59
Hypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes. Proc Natl Acad Sci U S A (1976) 1.59
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A (1999) 1.58
Occult polymicrobial endocarditis with Haemophilus parainfluenzae in intravenous drug abusers. Am J Med (1989) 1.57
Hyperglucagonaemia after burns. Lancet (1974) 1.56
Short-term and long-term mortality in very elderly patients admitted to an intensive care unit. Intensive Care Med (2006) 1.55
Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci U S A (1998) 1.53
Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes. J Biol Chem (1996) 1.53
Quality of life and metabolic control in patients with diabetes mellitus type 1 treated by continuous subcutaneous insulin infusion or multiple daily insulin injections. Neth J Med (2004) 1.52
Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia (1995) 1.52
The Banting Memorial Lecture 1975. Diabetes and the alpha cell. Diabetes (1976) 1.51
Evidence that down-regulation of beta-cell glucose transporters in non-insulin-dependent diabetes may be the cause of diabetic hyperglycemia. Proc Natl Acad Sci U S A (1990) 1.51
Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost (2013) 1.50
Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J Clin Invest (1992) 1.50
Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost (1996) 1.47
More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling. Diabetes (1994) 1.45
Effects of secretin on insulin and glucagon in portal and peripheral blood in man. Lancet (1966) 1.44
Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) (2007) 1.43
Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest (1969) 1.42
Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies. Eur Rev Med Pharmacol Sci (2015) 1.42
Meticulous control of diabetes: benefits, risks, and precautions. Diabetes (1982) 1.41
Absence of Pneumocystis jiroveci pneumonia in liver transplantation recipients receiving short-term (3-month) prophylaxis. Transpl Infect Dis (2008) 1.41
A novel leptin receptor isoform in rat. FEBS Lett (1996) 1.40
Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia (2004) 1.40
Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem (1998) 1.39
[A patient with repeated, life-threatening gastro-intestinal haemorrhages treated by means of medication, open surgery, endoscopic surgery, intervention radiology and conservative methods]. Ned Tijdschr Geneeskd (2007) 1.39
PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A (2002) 1.39
Additive effect of dDAVP and standard heparin in increasing plasma t-PA. Thromb Haemost (1989) 1.39
[Diagnostic and pharmaco-therapeutic options in acute severe blood loss]. Ned Tijdschr Geneeskd (2004) 1.39
[Anticoagulant treatment of patients with atrial fibrillations: dependent on age and other risk factors for thromboembolism]. Ned Tijdschr Geneeskd (2002) 1.39
The effect of insulin on the alpha-cell response to hyperglycemia in long-standing alloxan diabetes. J Clin Invest (1974) 1.39
The compliance with antidepressants in general practice. J Psychopharmacol (1994) 1.39
[Reasons why patients do or do not participate in clinical trials; a systemic review of the literature]. Ned Tijdschr Geneeskd (2004) 1.38